Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?

J Heart Lung Transplant. 2020 Jul;39(7):729-730. doi: 10.1016/j.healun.2020.04.007. Epub 2020 Apr 17.

Authors

Roberto Badagliacca¹, Susanna Sciomer², Nicola Petrosillo³

Affiliations

¹ Department of Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy. Electronic address: roberto.badagliacca@uniroma1.it.
² Department of Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy.
³ National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus*
COVID-19
Coronavirus Infections / complications*
Coronavirus Infections / therapy
Endothelin Receptor Antagonists / therapeutic use*
Humans
Pandemics
Pneumonia, Viral / complications*
Pneumonia, Viral / therapy
Pulmonary Arterial Hypertension / complications
Pulmonary Arterial Hypertension / drug therapy*
SARS-CoV-2
Viral Regulatory and Accessory Proteins / physiology*
Viroporin Proteins

Substances

Endothelin Receptor Antagonists
ORF3a protein, SARS-CoV-2
Viral Regulatory and Accessory Proteins
Viroporin Proteins